The Evolving Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.